DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

DIA Global Center

2017 年 09 月 11 日 8:15 上午 - 2017 年 09 月 12 日 3:30 下午

21 Dupont Circle NW, Suite 300, Washington, DC 20036

Navigating Chemistry, Manufacturing, and Controls Through the Drug Development Process

Sessions 6, 7, 8, 9, and 10

Session Chair(s)

Albert S. Yehaskel, MBA

Albert S. Yehaskel, MBA

President and CEO

Refuah Global Pharmaceutical Development, Inc., United States

Session 6: The EU Investigational Medicinal Product Dossier

  • Scope
  • Required Information
  • Structure
Session 7: Environmental Impact (IND and NDA)
  • Categorical Exclusions
  • Contents of a Categorical Exclusion Claim
  • Environmental Assessments
Session 8: Designing the Clinical Trial Material (CTM) Label
  • Salient Features of a CTM Label
  • Sample CTM Label and Carton label
  • CMC Issues in Finalizing your CTM
Session 9: From Clinical Trial Material to Commercial Product
  • Begin with the End in Mind
  • What is a Target Product Profile
  • Design Your Ideal Label
  • TOC for a Target Product Profile (TPP)
  • Changes to CTMs
  • References
Session 10: Special Protocol Assessment
  • Purpose and Types of SPAs
  • Procedure for Request and Stability Protocol
  • Format and Content of an SPA
  • Binding Nature of SPAs

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。